All In Biotech

Drug Trial Radar · NCT07246863

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

131

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

Oct 1, 2029

Study completion Oct 1, 2031

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Conditions

  • Metastatic Non-Squamous Non-Small Cell Lung Cancer
  • Adult Solid Tumor

Interventions

  • Visugromab RDE (recommended dose for expansion)Biological

    Participants receive Visugromab (RDE) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)

  • Visugromab 6mg/kgBiological

    Participants receive Visugromab (6mg/kg) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)

  • NivolumabBiological

    Participants receive Nivolumab 360mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)

  • Placebo Saline InfusionOther

    Participants receive Saline intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)

  • DocetaxelDrug

    Participants receive Docetaxel 75 mg/m2 intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: up to 36 months

Locations

36 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

    Birmingham, Alabama · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • NYU Langone Hospital - Long Island

    Mineola, New York · Recruiting

  • NYU Longone Health

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Hospital Esslingen GmbH

    Esslingen am Neckar, Baden-Wurttemberg, Germany · Recruiting

  • Thorax Clinic Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • University Hospital Wuerzburg, Clinic and Polyclinic II for Gastroenterology, Hematology, Internal Oncology, Stem Cell Therapies, Hepatology, Infectiology, Psychosomatics and Rheumatology/ Clinical Immunology

    Würzburg, Bavaria, Germany · Recruiting

  • Evangelical Hospital Bethel, Clinic for Internal Medicine, Hematology/Oncology, Palliative Medicine Johannesstift

    Bielefeld, North Rhine-Westphalia, Germany · Recruiting

  • Clinics Essen-Mitte

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Foundation Bethanien Moers

    Moers, North Rhine-Westphalia, Germany · Recruiting

  • Local Health Unit of Romagna - Santa Maria delle Croci Hospital of Ravenna, Onco-Hematology Department

    Ravenna, Italy · Recruiting

  • Institute of Romagna for Cancer Research "Dino Amadori" - IRCCS IRST

    Forlì, Emilia-Romagna, Italy · Recruiting

  • Oncology Reference Center

    Aviano, Friuli Venezia Giulia, Italy · Recruiting

  • National Cancer Institute Regina Elena, IRCCS

    Rome, Lazio, Italy · Recruiting

  • European Institute of Oncology (IEO), IRCCS

    Milan, Milan, Italy · Recruiting

  • Institute of Cancer Research and Treatment of Candiolo

    Candiolo, Turin, Italy · Recruiting

  • MED-Polonia, Sp. z o.o. (LLC)

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Sf. Nectarie Oncology Center

    Craiova, Dolj, Romania · Recruiting

  • Clinica Polisano S.R.L

    Sibiu, Sibiu County, Romania · Recruiting

  • SC Oncomed SRL

    Timișoara, Timiș County, Romania · Recruiting

  • University Hospital Lucus Augusti (HULA)

    Lugo, Spain · Recruiting

  • University Hospital of Jaen

    Jaén, Andalusia, Spain · Recruiting

  • Regional University Hospital of Malaga

    Málaga, Andalusia, Spain · Recruiting

  • University Hospital Virgen del Rocio (HUVR)

    Seville, Andalusia, Spain · Recruiting

  • Hospital Quiron Dexeus Barcelona

    Barcelona, Barcelona, Spain · Recruiting

  • Hospital Clinic of Barcelona

    Barcelona, Catalonia, Spain · Recruiting

  • University Hospital Complex of Santiago (CHUS)

    Santiago de Compostela, Galicia, Spain · Recruiting

  • University Hospital of Girona Dr. Josep Trueta

    Girona, Girona, Spain · Recruiting

  • START- Rioja

    Logroño, La Rioja, Spain · Recruiting

  • Clínica Universidad de Navarra

    Madrid, Madrid, Spain · Recruiting

  • University Hospital 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

  • University Hospital HM Sanchinarro

    Madrid, Madrid, Spain · Recruiting

  • University Clinic of Navarra - Pamplona

    Pamplona, Navarre, Spain · Recruiting

  • University Hospital Basel

    Basel, Switzerland · Recruiting

  • Cantonal Hospital Saint Gallen, Clinic of Oncology and Hematology

    Sankt Gallen, Switzerland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.